The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a greater substantial loss in body weight and improve metabolic markers,